Quantcast

Byetta Lawyers at Gilman Law, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Troubled by Growing Byetta Pancreatic Cancer Reports

May 20, 2013

Gilman Law LLP is Investigating Byetta Lawsuits on Behalf of Victims of Pancreatic Cancer Side Effects, Allegedly Associated with Byetta, Januvaia, Victoza, and other Diabetes Drugs Known as Incretin Mimetics.

Boston, MA (PRWEB) May 20, 2013

Gilman Law LLP, a leading pharmacy law and defective drug plaintiffs´ law firm investigating Byetta lawsuits, is troubled by a new study that reveals that pancreatic cancer reports associated with Byetta and similar type 2 diabetes drugs are growing. The analysis, conducted by the Institute for Safe Medication Practices (ISMP), found that 71 Byetta pancreatic cancer reports had been made to the U.S. Food & Drug Administration (FDA) as of June 30, 2012. Overall, Byetta and other incretin mimetics were associated with 105 reports of pancreatic cancer and 831 reports of pancreatitis, a known risk factor for pancreatic cancer. The analysis appears in the ISMP´s April 2013 QuarterWatch report.

http://www.ismp.org/quarterwatch/pdfs/2012Q3.pdf

The defective drug and products liability law firm of Gilman Law LLP is providing free Byetta lawsuit consultations to individuals who have allegedly suffered serious side effects of the pancreas, including pancreatitis and pancreatic cancer. Potential claimants should be aware that Byetta lawsuits, like all personal injury claims, are subject to a strict statute of limitations that varies by state. To ensure that their right to recovery is not put in jeopardy, individuals seeking to file a Byetta lawsuit are urged to contact our defective drug lawyers today, TOLL FREE at 888-252-0048 or submit a free legal consultation form online.

Byetta and other incretin mimetics work by mimicking the incretin hormones that the body usually produces naturally to stimulate the release of insulin in response to a meal. In March 2013, the FDA announced it had launched a safety review of incretin mimetics, following a study that linked the drugs to high rates of hospitalization for pancreatitis, as well as precancerous lesions in the pancreas of patients who take the drugs. In addition to Byetta, the FDA was also investigating a number of other incretin mimetics, including Bydureon, Janumet, Janumet XR, Januvia, Juvisync, Kazano, Kombiglyze XR, Nesina, Onglyza, Oseni, Tradjenta, and Victoza.

http://www.fda.gov/Drugs/DrugSafety/ucm343187.htm

On April 5th, plaintiffs petitioned the U.S. Judicial Panel on Multidistrict Litigation (JPML) to form a multidistrict litigation for all pending and future lawsuits filed on behalf of individuals who developed pancreatic cancer, allegedly due to the use of Byetta and other incretin mimetics. Oral Arguments on the matter are scheduled for May 30th. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL Pending No. 46 (JPML))

http://www.jpml.uscourts.gov/sites/jpml/files/Hearing_Order-5-30-13.pdf

Gilman Law LLP is providing complimentary lawsuit evaluations to users of Byetta and other incretin mimetics who developed pancreatitis or pancreatic cancer that may be associated with the use of these drugs. For more information, please contact Gilman Law LLP today by visiting our website to fill out a free, no obligation case evaluation form, or call Toll Free at 1-888-252-0048.

About Gilman Law LLP

Gilman Law LLP, a leading pharmaceutical law and defective drug law firm, has been recognized for delivering successful results to their clients across a broad range of claims stemming from consumer product injury, mass tort, and class action lawsuits. For over 33 years, the Gilman Law LLP team of highly experienced lawyers has earned renown for tireless work on behalf of their clients on many of today´s most challenging and important legal issues.

Contact:

Gilman Law LLP

Beachway Professional Center Tower

Suite 525-405

8951 Bonita Beach Road

Bonita Springs, FL 34135

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/5/prweb10736284.htm


Source: prweb



comments powered by Disqus